跳至主要内容
临床试验/CTRI/2019/05/019049
CTRI/2019/05/019049进行中(未招募)2 期

Study of GVDexa regimen as salvage therapy in relapsed/ refractory Hodgkin’s lymphoma

JIPMER0 个研究点目标入组 9 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
JIPMER
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Relapsed/ refractory Hodgkin’s Lymphoma having previously received at least 1 line of standard chemotherapy
  • Age 5- 65 years at the time of enrolmemt
  • ECOG performance status 0 to 1
  • Written informed consent for adults over 18 years of age, and consent from parents/ legal guardian for those below 18 years of age
  • Negative serum pregnancy test
  • Female patients in the reproductive age group MUST AGREE TO use suitable contraception during the course of therapy
  • Patients with relapsed or refractory disease following stem cell transplantation are permitted
  • Acceptable bone marrow and organ function at screening as described below:
  • a. ANC more than 1500 per mic.L (without WBC growth factor support)
  • b. Platelet count more than 75,000 per mic.L;
  • c. Hemoglobin more than 9 g per dL
  • d. Total Bilirubin less than 1.5 x ULN;
  • e. AST (SGOT) less than 3 x ULN (less than 5 × ULN if known liver metastases)
  • f. ALT (SGPT) less than 3 x ULN (less than 5 × ULN if known liver metastases)
  • g. Serum creatinine less than 2 mg/dL or a measured creatinine clearance more than 40 mL/min
  • according to Cockcroft-Gault formula
  • Measurable disease must be present either on physical examination or imaging studies; non- measurable disease alone is not acceptable

排除标准

  • f. Human Immunodeficiency Virus (HIV) infection/and or Anti-retroviral therapy and or HCV infection (patients who are anti-HCV positive but have been treated and have undetectable viral load would be permitted to be part of the study).
  • g. Active Hepatitis B infection (in patients who are Hepatitis B carriers, the markers of active infection such as HbeAg and HBV DNA titers must be negative and patients would be continued on appropariate prophylaxis with antivirasl throughout the duration of the study).
  • h. History of allogeneic transplant
  • i. Patient with known peptic ulcer disease/ history of GI perforation due to peptic ulcer in the past.
  • j. Uncontrolled medical conditions including but not limited to diabetes mellitus and hypertension.
  • k. Pre-existing peripheral neuropathy of > grade 1
  • l. Relapse within 6 months of autologous transplant

研究者

发起方
JIPMER

相似试验